Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: The use of sobetirome or a prodrug or derivative thereof, including Sob-AM2, for treating a disease, disorder, or condition associated with or suspected of being associated with dysmyelination, such as Pitt-Hopkins Syndrome, is disclosed.

Abstract: Systems and methods initiate displaying a first GUI of an integrated platform that interconnects transfer source(s) and transfer destination(s), wherein access to the integrated platform is restricted to registered users, and end user data of at least one of the transfer destination(s) are at least partially obtained from user responses to system prompts displayed via the first GUI and from user activities of user(s) of the transfer destination(s). End user data is applied to a deployed AI model to identify resource(s) available for transfer to generate a listing of the resource(s), and a probability score indicating a likelihood the user(s) will be interested is assigned to the resource(s) and sorted to prioritize highest scored resources. Display of a customized second GUI including the listing of the resource(s) is initiated.

Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: The invention provides non-steroidal ligands for the androgen receptor, methods for making non-steroidal ligands of the androgen receptor, compositions of non-steroidal ligands of the androgen receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the androgen receptor for treating or preventing diseases (e.g., prostate cancer) associated with androgen binding to the androgen receptor.

Abstract: There is provided a liquid filter comprising a filter vessel having a removable cover, a fluid inlet, an engagement lip for a filter and a fluid outlet, an open top, fluid impermeable sidewalls, and a fluid outlet at a bottom of the insert. Into the filter vessel is inserted a water impermeable insert having an insert lip engageable in a sealing relationship with the filter vessel engagement lip. A single cartridge filter is inserted within the cartridge filter insert having a generally solid top surface, a bottom fluid outlet sealingly engageable with the insert outlet and a filter material. The cartridge filter top surface forms a weir for diverting fluid to be filtered toward an annular opening created between the filter cartridge and the insert, the annular opening having a cross sectional area, which generally is from 25 to 100% of the cross sectional area of the filter cartridge outlet opening.

Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.

Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.

Abstract: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.

Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed.

Abstract: The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor.